CL2012000694A1 - Composicion farmaceutica que comprende 200-800mg de ceftarolina fosamilo, l-arginina y menos de 2% de un aducto de l-arginina; uso para tratar infecciones de la piel y neumonia bacteriana. - Google Patents

Composicion farmaceutica que comprende 200-800mg de ceftarolina fosamilo, l-arginina y menos de 2% de un aducto de l-arginina; uso para tratar infecciones de la piel y neumonia bacteriana.

Info

Publication number
CL2012000694A1
CL2012000694A1 CL2012000694A CL2012000694A CL2012000694A1 CL 2012000694 A1 CL2012000694 A1 CL 2012000694A1 CL 2012000694 A CL2012000694 A CL 2012000694A CL 2012000694 A CL2012000694 A CL 2012000694A CL 2012000694 A1 CL2012000694 A1 CL 2012000694A1
Authority
CL
Chile
Prior art keywords
arginine
ceftaroline
pharmaceutical composition
phosamyl
adduct
Prior art date
Application number
CL2012000694A
Other languages
English (en)
Inventor
Dirk Talbot George Thye
Original Assignee
Pfizer Anti Infectives Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43757152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000694(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Anti Infectives Ab filed Critical Pfizer Anti Infectives Ab
Publication of CL2012000694A1 publication Critical patent/CL2012000694A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Método para tratar una infección bacteriana con ceftarolina en solución acuosa; composición farmacéutica que comprende ceftarolina.
CL2012000694A 2009-09-21 2012-03-20 Composicion farmaceutica que comprende 200-800mg de ceftarolina fosamilo, l-arginina y menos de 2% de un aducto de l-arginina; uso para tratar infecciones de la piel y neumonia bacteriana. CL2012000694A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24412009P 2009-09-21 2009-09-21
US29490110P 2010-01-14 2010-01-14

Publications (1)

Publication Number Publication Date
CL2012000694A1 true CL2012000694A1 (es) 2012-08-31

Family

ID=43757152

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000694A CL2012000694A1 (es) 2009-09-21 2012-03-20 Composicion farmaceutica que comprende 200-800mg de ceftarolina fosamilo, l-arginina y menos de 2% de un aducto de l-arginina; uso para tratar infecciones de la piel y neumonia bacteriana.

Country Status (24)

Country Link
US (2) US20110071114A1 (es)
EP (1) EP2480236A4 (es)
KR (1) KR20120083344A (es)
CN (1) CN102781451A (es)
AU (1) AU2010295269B2 (es)
BR (1) BR112012006250B1 (es)
CA (1) CA2774772A1 (es)
CL (1) CL2012000694A1 (es)
CO (1) CO6531417A2 (es)
CR (1) CR20120137A (es)
CU (1) CU20120048A7 (es)
DO (1) DOP2012000077A (es)
EA (1) EA029149B1 (es)
EC (1) ECSP12011739A (es)
GT (1) GT201200082A (es)
HN (1) HN2012000585A (es)
IL (1) IL218349A0 (es)
MX (2) MX2012003201A (es)
NI (1) NI201200045A (es)
PE (2) PE20171176A1 (es)
PH (1) PH12012500528A1 (es)
SG (1) SG178936A1 (es)
WO (1) WO2011035305A1 (es)
ZA (1) ZA201202924B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
TWI565706B (zh) 2011-06-17 2017-01-11 阿斯特捷利康公司 用於製備包括反－７－酮基－６－（磺酸氧基）－１，６－二氮雜雙環［３，２，１］辛烷－２－甲醯胺之雜環化合物及其鹽類之方法
CN107621512B (zh) * 2017-11-02 2020-07-31 扬子江药业集团有限公司 一种柱前衍生化法测定头孢洛林酯侧链酰氯纯度的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW473479B (en) * 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
DK1310502T3 (da) * 2000-08-10 2009-09-07 Takeda Pharmaceutical Phosphonocephem-forbindelse
WO2002093162A2 (en) * 2001-05-17 2002-11-21 Mcgill University Individualization of therapy with antibiotic agents
IL163666A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2008302201A1 (en) * 2007-09-21 2009-03-26 Astrazeneca Ab Soluble dosage forms containing cephem derivatives suitable for parenteral administration

Also Published As

Publication number Publication date
MX2012003411A (es) 2012-04-30
ZA201202924B (en) 2012-12-27
NI201200045A (es) 2012-11-02
US20150258126A1 (en) 2015-09-17
US20110071114A1 (en) 2011-03-24
EP2480236A4 (en) 2013-04-17
WO2011035305A1 (en) 2011-03-24
IL218349A0 (en) 2012-04-30
CO6531417A2 (es) 2012-09-28
ECSP12011739A (es) 2012-05-30
AU2010295269B2 (en) 2014-06-05
MX2012003201A (es) 2012-05-08
EA029149B1 (ru) 2018-02-28
EP2480236A1 (en) 2012-08-01
PH12012500528A1 (en) 2019-06-14
HN2012000585A (es) 2015-06-15
AU2010295269A1 (en) 2012-04-12
CU20120048A7 (es) 2012-10-15
CN102781451A (zh) 2012-11-14
DOP2012000077A (es) 2012-05-31
US9629861B2 (en) 2017-04-25
BR112012006250A2 (pt) 2016-05-31
CR20120137A (es) 2012-05-28
EA201200501A1 (ru) 2012-10-30
GT201200082A (es) 2014-12-22
SG178936A1 (en) 2012-04-27
BR112012006250B1 (pt) 2021-07-06
PE20121819A1 (es) 2013-02-01
CA2774772A1 (en) 2011-03-24
PE20171176A1 (es) 2017-08-22
KR20120083344A (ko) 2012-07-25

Similar Documents

Publication Publication Date Title
EA201791850A1 (ru) Борсодержащие малые молекулы
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
MX2015011613A (es) Composiciones antimicrobianas-antibiopelicula y metodos para utlizarlas.
CL2012003168A1 (es) Composicion farmaceutica que comprende una solucion acuosa de minociclina y un cation divalente o trivalente en una proporcion mayor de 2:1 con respecto a la minociclina; metodo de preparacion; kit y uso en el tratamiento de infecciones bacterianas.
EA201270566A1 (ru) Противомикробные соединения и способы их получения и применения
CL2008001367A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion bacteriana.
EA201270567A1 (ru) Противомикробные соединения и способы их получения и применения
CL2012001336A1 (es) Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas.
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
BRPI0913300A2 (pt) composto, processo para o preparo e uso do mesmo, método de tratamento de infecção bacteriana em um animal, e, composição farmacêutica.
CL2009000902A1 (es) Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica.
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
BR112013024974A2 (pt) composto, composição farmacêutica, método para o tratamento de infecções virais, e, processo para preparar um composto
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
CL2012002902A1 (es) Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas.
CL2007002862A1 (es) Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.
CO2019008575A2 (es) Métodos para tratar infecciones bacterianas
CL2012003626A1 (es) Uso de acido cicorico y una bacteria acido lactica para regular la pigmentacion de la piel; metodo de tratamiento estetico; kit para prevenir transtornos de pigmentacion de la piel y/o imperfecciones de la piel.
CL2011002649A1 (es) Uso de un aerosol que comprende levofloxacina u ofloxacina para preparar un medicamento util para el tratamiento de una infeccion bacteriana pulmonar.
CL2012000694A1 (es) Composicion farmaceutica que comprende 200-800mg de ceftarolina fosamilo, l-arginina y menos de 2% de un aducto de l-arginina; uso para tratar infecciones de la piel y neumonia bacteriana.
PL386175A1 (pl) Nowe szczepy bakteriofagów do leczenia zakażeń bakteryjnych, zwłaszcza szczepami bakterii lekoopornych rodzaju Enterococcus
BR112012033121A2 (pt) métodos e composições farmacêuticas para o tratamento de infecções do trato respiratório.
CL2012003250A1 (es) Uso de un galactolipido en combinacion con acido ascorbico y/o un derivado del mismo que sirve para proteger una composicion contra la oxidacion; metodo para la preparacion de la composicion, composicion; y producto.